Monday, January 22, 2007
Friday, January 19, 2007
Cox-2 pain drugs attempt quiet comeback after safety concerns
Cox-2 pain drugs attempt quiet comeback after safety concerns
By Jeanne Whalen
The Wall Street Journal Europe
19 Jan 2007
Twoyears afterMerck& Co. was forced to pull the painkiller Vioxx fromthe global market owing to cardiovascular side effects, similar pain pills known as Cox-2 inhibitors are quietly attempting a comeback. Drug giant Novartis AG said Thursday that it... read more...
By Jeanne Whalen
The Wall Street Journal Europe
19 Jan 2007
Twoyears afterMerck& Co. was forced to pull the painkiller Vioxx fromthe global market owing to cardiovascular side effects, similar pain pills known as Cox-2 inhibitors are quietly attempting a comeback. Drug giant Novartis AG said Thursday that it... read more...
Friday, January 12, 2007
AstraZeneca to develop drugs with Bristol-Myers
AstraZeneca to develop drugs with Bristol-Myers
By Jeanne Whalen
The Wall Street Journal Europe
12 Jan 2007
In an unusual arrangement between fiercely competitive pharmaceutical giants, AstraZeneca PLC and Bristol-Myers Squibb Co. have struck a partnership to develop and market two experimental drugs for Type 2 diabetes discovered by... read more...
By Jeanne Whalen
The Wall Street Journal Europe
12 Jan 2007
In an unusual arrangement between fiercely competitive pharmaceutical giants, AstraZeneca PLC and Bristol-Myers Squibb Co. have struck a partnership to develop and market two experimental drugs for Type 2 diabetes discovered by... read more...
Thursday, January 04, 2007
Inside Abbott’s tactics to save AIDS drug
Inside Abbott’s tactics to save AIDS drug
By John Carreyrou
The Wall Street Journal Europe
04 Jan 2007
Inthefallof2003, AbbottLaboratoriesgrewworriedaboutnewcompetition to its flagship AIDS drug, Kaletra. Thenit seizedonanunusual weapon that helped Kaletra’s global sales top $1 billion a year, even as it exposed Abbott to criticism that it was... read more...
By John Carreyrou
The Wall Street Journal Europe
04 Jan 2007
Inthefallof2003, AbbottLaboratoriesgrewworriedaboutnewcompetition to its flagship AIDS drug, Kaletra. Thenit seizedonanunusual weapon that helped Kaletra’s global sales top $1 billion a year, even as it exposed Abbott to criticism that it was... read more...